With the development and distribution of COVID-19 vaccines, the global health crisis is beginning to take a turn in some parts of the world. These changes have brought a strong desire to shift certain practices back to pre-pandemic norms — including a return to on-site inspections and audits.

Now drug and devicemakers are faced with the question of how to most effectively merge the best practices for conducting inspections before and during the COVID-19 crisis. It’s a task without a playbook but there are avenues to create one.

Regulatory agencies have developed guidance on conducting virtual audits and there have long been guidelines around on-site audits. This webinar will bring those two sets of expectations together to consider how post-pandemic audits may look. Regulatory compliance experts Sue Schniepp, Seyed Khorashahi and Steve Lynn will share insights on the likely structure of blended on-site and virtual inspections and audits. They will explore how these merged best practices will likely move forward and tips for developing an efficient, effective model.

Webinar Takeaways:

  • Virtual Audit Practices
    1. Best practices for conducting virtual audits
  • On-site Audit Practices
    1. Best practices for conducting on-site audits
  • Models for Post-Pandemic Audits
    1. Frameworks for combining virtual audits and on-site audits
    2. Improving effectiveness and efficiency
    3. Maintaining oversight of suppliers, contract manufacturers and test laboratories
    4. Understanding the operational changes needed to keep facilities safe during on-site inspections


The world will soon be returning to many pre-pandemic practices, including on-site audits and inspections. Get prepared for these changes and find the insights you need to merge your virtual practices with on-site interactions during this webinar.


Who Will Benefit:

  • Pharmaceutical, biological and medical device companies
  • Supplier and contract manufacturing companies
  • Contract testing laboratories
  • Auditors
  • Audit managers
  • Quality assurance and quality control leaders
  • Operations directors
  • Operations personnel
  • Regulatory affairs leadership